OncoMatch/Clinical Trials/NCT05978193

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Is NCT05978193 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Immunotherapy and Chemotherapy for esophageal squamous cell carcinoma.

Phase 2RecruitingShanghai Chest HospitalNCT05978193Data as of May 2026

Treatment: Immunotherapy · Chemotherapy — SCR-ESCC-01 is a multicenter, randomized, phase II study aiming to investigate the benefit of early involvement of low-dose radiotherapy(LDRT) and conventionally fractionated radiotherapy(CFRT) in the first-line anti-PD-1 based treatment of metastatic ESCC. It begins with a safety run-in phase, followed by a randomized controlled comparison against standard immunochemotherapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Disease stage

Required: Stage IVB

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: anti-tumor therapy

No prior anti-tumor treatment

Cannot have received: surgery

Any prior anti-tumor therapy for esophageal cancer, i.e., surgery, radiotherapy, chemotherapy, or immunotherapy

Cannot have received: radiotherapy

Any prior anti-tumor therapy for esophageal cancer, i.e., surgery, radiotherapy, chemotherapy, or immunotherapy

Cannot have received: chemotherapy

Any prior anti-tumor therapy for esophageal cancer, i.e., surgery, radiotherapy, chemotherapy, or immunotherapy

Cannot have received: immunotherapy

Any prior anti-tumor therapy for esophageal cancer, i.e., surgery, radiotherapy, chemotherapy, or immunotherapy

Lab requirements

Blood counts

Adequate hematologic function that meets the requirements for chemotherapy and immunotherapy assessed by investigators

Kidney function

Adequate renal function that meets the requirements for chemotherapy and immunotherapy assessed by investigators

Liver function

Adequate hepatic function that meets the requirements for chemotherapy and immunotherapy assessed by investigators

Cardiac function

Adequate cardiac function that meets the requirements for chemotherapy and immunotherapy assessed by investigators

Adequate hematologic, renal, hepatic, and cardiac functions that meet the requirements for chemotherapy and immunotherapy assessed by investigators

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify